INVESTIGADORES
GARIBOTTO Francisco Matias
congresos y reuniones científicas
Título:
Hidroxynaphthalenecarboxamides and substituted piperazinylpropandiols, two new series of BRAF inhibitors. A theoretical and experimental study
Autor/es:
CAMPOS, LUDMILA E.; GARIBOTTO, FRANCISCO M.; VETTORAZZI MARCELA; ANGELINA, EMILIO; ALVAREZ, SERGIO E.; ENRIZ, RICARDO D.
Lugar:
San Luis
Reunión:
Congreso; XLVIII Reunión Anual de la Sociedad Argentina de Biofísica; 2019
Institución organizadora:
Universidad Nacional de San Luis
Resumen:
Recently we reported two new structural scaffolds as potential inhibitors of BRAF1; both series of compounds were studied in greater depth in the present work. Our results indicate that the new substituted piperazinylpropandiols derivatives evaluated here do not show significantly better activities to that previously reported for the structure chosen as starting structure. In contrast the results obtained for the other series were more positive. We report now new hydroxynaphthalenecarboxamides with significant inhibitory activity on BRAF. In order to better understand these experimental results, we carried out a Molecular modeling study using different combined techniques. While the simulations using simple techniques such as docking and DM simulations allowed us to explain which the best structural scaffold, these results is do not allow to explain why compounds with substituents in different spatial positions have similar inhibitory effects. In this sense, the use of MD/QTAIM combined calculations allow to explain in detail the molecular interactions that stabilize the different molecular complexes reported here. Another interesting contribution of this study is that the different molecular interactions that stabilize the complexes have been analyzed in depth. The QTAIM results indicatethat the different spatial dispositions of the substituents (ortho, meta and para) allow to establish alternative interactions with Asp594 or with Lis483 depending on their spatial arrangement. This result is in agreement to those observed for vemurafenib and dabrafenib. This structural information is important for the design of new inhibitors with this type of structural scaffold.